All HER2-IgE variants recognized HER2 on three different HER2-expressing breast cancer cell lines (ZR-75-30, SK-BR-3 and BT-474) and bound in a dose-dependent manner, with no obvious impact of their glycosylation profiles (Figure 3A). This evidence concerns the gene IGHE and breast cancer.